570 related articles for article (PubMed ID: 33793331)
1. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
Savoia C; Volpe M; Kreutz R
Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
3. Hypertension and COVID-19: Current Evidence and Perspectives.
Gallo G; Calvez V; Savoia C
High Blood Press Cardiovasc Prev; 2022 Mar; 29(2):115-123. PubMed ID: 35184271
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
Edmonston DL; South AM; Sparks MA; Cohen JB
Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
[TBL] [Abstract][Full Text] [Related]
5. Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.
Jiang X; Eales JM; Scannali D; Nazgiewicz A; Prestes P; Maier M; Denniff M; Xu X; Saluja S; Cano-Gamez E; Wystrychowski W; Szulinska M; Antczak A; Byars S; Skrypnik D; Glyda M; Król R; Zywiec J; Zukowska-Szczechowska E; Burrell LM; Woolf AS; Greenstein A; Bogdanski P; Keavney B; Morris AP; Heagerty A; Williams B; Harrap SB; Trynka G; Samani NJ; Guzik TJ; Charchar FJ; Tomaszewski M
Eur Heart J; 2020 Dec; 41(48):4580-4588. PubMed ID: 33206176
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.
Siri-Angkul N; Chattipakorn SC; Chattipakorn N
J Physiol; 2020 Oct; 598(19):4181-4195. PubMed ID: 32710575
[TBL] [Abstract][Full Text] [Related]
8. Delineating clinical characteristics and comorbidities among 206 COVID-19 deceased patients in India: Emerging significance of renin angiotensin system derangement.
Majeed J; Ajmera P; Goyal RK
Diabetes Res Clin Pract; 2020 Sep; 167():108349. PubMed ID: 32712124
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 and renin-angiotensin system modulators: what do we know so far?
de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
[TBL] [Abstract][Full Text] [Related]
10. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
11. Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.
Pucci F; Bogaerts P; Rooman M
Viruses; 2020 Nov; 12(12):. PubMed ID: 33265982
[TBL] [Abstract][Full Text] [Related]
12. The concern about ACE/ARB and COVID-19: Time to hold your horses!
Pergolizzi JV; Varrassi G; Magnusson P; LeQuang JA; Leopoulou M; Paladini A; Taylor R; Wollmuth C; Breve F;
J Am Pharm Assoc (2003); 2020; 60(6):e88-e90. PubMed ID: 32747165
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
Oz M; Lorke DE; Kabbani N
Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
[TBL] [Abstract][Full Text] [Related]
14. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
South AM; Brady TM; Flynn JT
Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
[TBL] [Abstract][Full Text] [Related]
15. Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.
Tsampasian V; Corballis N; Vassiliou VS
Curr Hypertens Rep; 2022 Oct; 24(10):425-433. PubMed ID: 35716247
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
17. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.
Singh AK; Gupta R; Misra A
Diabetes Metab Syndr; 2020; 14(4):283-287. PubMed ID: 32283499
[TBL] [Abstract][Full Text] [Related]
18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
19. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Vázquez-Cornejo E
Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
[TBL] [Abstract][Full Text] [Related]
20. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Kreutz R; Algharably EAE; Azizi M; Dobrowolski P; Guzik T; Januszewicz A; Persu A; Prejbisz A; Riemer TG; Wang JG; Burnier M
Cardiovasc Res; 2020 Aug; 116(10):1688-1699. PubMed ID: 32293003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
